-- 根據週三提交給香港交易所的文件顯示，先聲藥業（HKG:2096）已獲得中國監管機構批准，可以開始其註射劑SIM0613的臨床試驗。 該注射用於治療晚期實體瘤，在大中華區以外的地區，其銷售許可已授予益普生製藥。
Related Articles
Asia
Resolution Minerals Reports High Grade of Antimony Recoveries on Idaho Project Samples
Resolution Minerals (ASX:RML) reported high rates of antimony recoveries in sulfides during concentrate test work on samples from the Antimony Ridge project in Idaho, according to a Wednesday filing with the Australian bourse.The high sulfide recoveries were achieved from lower grade samples containing about 10% antimony, suggesting potential to capture stibnite, even if high-grade ore is diluted by surrounding waste during extraction, the filing said.Further concentration stages are underway in test work on samples from the project, per the filing.Shares fell nearly 2% in midday trade Wednesday.
$ASX:RML
International
Beijing Tourism Revenue Up 7% During May Day Holiday
Beijing generated 22.4 billion yuan in tourism revenue during the five-day May Day holiday, a 6.6% year-on-year increase, according to the Beijing Municipal Bureau of Culture and Tourism.China's capital city received 18.8 million tourist visits, up 5.1%. Inbound visits rose 22.3% to 128,000, with spending reaching 1.38 billion yuan.Beijing hosted over 2,000 cultural activities, including 1,684 live performance sessions, generating 260 million yuan in box office revenue.
$^SSEC$^SZSE
Asia
Korea Exchange Halts Kospi Trading for Five Minutes After Buying Surges on Iran Conflict De-escalation Hopes
The Korea Exchange activated a five-minute buy-side sidecar on the country's primary stock market on Wednesday morning as investors rushed to purchase securities on hopes that the U.S.-Iran conflict may end in the near future.The Korea Exchange announced the order at 9:06 am after the KOSPI200 Futures added 66.05 points, or 6.28%, to trade at 1,116.55.A buy-side sidecar is activated when the KOSPI200 Futures index gains 5% or more for at least one minute.
$^KS11